Analyst Activity – Maxim Group Reiterates Buy on Sonoma Pharmaceuticals (NASDAQ:SNOA)

Analyst Ratings For Sonoma Pharmaceuticals (NASDAQ:SNOA)

Story continues below

Today, Maxim Group reiterated its Buy rating on Sonoma Pharmaceuticals (NASDAQ:SNOA) with a price target of $11.00.

Some recent analyst ratings include

  • 2/8/2018-Maxim Group Reiterated Rating of Buy.
  • 12/28/2017-Benchmark initiated coverage with a Speculative Buy rating.

Recent Insider Trading Activity For Sonoma Pharmaceuticals (NASDAQ:SNOA)
Sonoma Pharmaceuticals (NASDAQ:SNOA) has insider ownership of 13.30% and institutional ownership of 9.20%.

  • On 11/29/2017 James J Schutz, CEO, bought 400 with an average share price of $5.03 per share and the total transaction amounting to $2,012.00.
  • On 11/29/2017 Robert E Miller, CFO, bought 1,790 with an average share price of $5.02 per share and the total transaction amounting to $8,985.80.
  • On 11/24/2017 James J Schutz, CEO, bought 254 with an average share price of $5.05 per share and the total transaction amounting to $1,282.70.
  • On 11/21/2017 Robert E Miller, CFO, bought 2,000 with an average share price of $5.03 per share and the total transaction amounting to $10,060.00.
  • On 8/10/2017 James J Schutz, CEO, bought 929 with an average share price of $5.46 per share and the total transaction amounting to $5,072.34.
  • On 8/10/2017 Marc Umscheid, Insider, bought 600 with an average share price of $5.31 per share and the total transaction amounting to $3,186.00.
  • On 8/10/2017 Robert E Miller, CFO, bought 2,264 with an average share price of $5.30 per share and the total transaction amounting to $11,999.20.

Recent Trading Activity for Sonoma Pharmaceuticals (NASDAQ:SNOA)
Shares of Sonoma Pharmaceuticals closed the previous trading session at 4.52 down -0.23 4.84% with 4.400000095367432 shares trading hands.

An ad to help with our costs